A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
Among 28,500 opioid-overdose survivors, 9% died and 21% had a repeat overdose within one year — roughly triple the prior literature estimate.
A JAMA Study Just Tripled the Repeat-Overdose Risk Estimate. The First 30 Days After ED Discharge Are the Inflection Point.
A new JAMA-published study of nearly 28,500 emergency-department-treated opioid-overdose survivors in Ontario between 2017 and 2023 found that 9% died and 21% experienced a repeat overdose within one year of discharge. The highest-risk window was the first 30 days, during which 2% of survivors died and 6% had a repeat overdose. The mortality rates are roughly three times higher than what earlier literature suggested — most of which was collected before fentanyl saturated the unregulated drug supply.
The clinical implication is direct: the moment an opioid-overdose survivor leaves the emergency department is the single highest-leverage handoff point in the entire SUD care pathway. The intervention bundle the study’s authors call for — guaranteed take-home naloxone, active warm handoff to medications for opioid use disorder (MOUD), and same-week peer follow-up — costs less per saved life than almost any other addiction intervention in the literature.
Why this matters for people in recovery
If you or someone you love is leaving an ED after an overdose: ask for a naloxone kit at discharge (most U.S. hospitals can provide one); ask whether the hospital can initiate buprenorphine on-site (most can, and the 24-hour window after an overdose is when this works best); and connect with a peer recovery coach or community navigation service before you leave the parking lot. The first 30 days are not the moment to wait for an appointment four weeks from Tuesday.
If you are in Arizona and looking for an ED-to-treatment connection that doesn’t fall through the cracks, Rize can help.
988 Suicide & Crisis Lifeline: Call or text 988. SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7.
Sources Cited
- 01.B
- 02.B
- 03.B
Filed Under
sciencebiologytreatment
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.